FDA also issued an EUA for casirivimab and imdevimab (REGN10933 and REGN10987), two monoclonal antibodies recognizing two different epitopes on the SARS-CoV-2 spike protein RBD. This authorization was based on a phase 2 study involving 799 non-hospitalized adult patients with mild-to-moderate...